R
Russell E. Ware
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 369
Citations - 16030
Russell E. Ware is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Sickle cell anemia & Anemia. The author has an hindex of 63, co-authored 344 publications receiving 14442 citations. Previous affiliations of Russell E. Ware include Duke University & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Charles J. Parker,Mitsuhiro Omine,Stephen J. Richards,Junichi Nishimura,Monica Bessler,Russell E. Ware,Peter Hillmen,Lucio Luzzatto,Neal S. Young,Taroh Kinoshita,Wendell F. Rosse,Gérard Socié +11 more
TL;DR: The primary clinical manifestations of paroxysmal nocturnal hemoglobinuria are hemolytic anemia, marrow failure, and thrombophilia.
Journal ArticleDOI
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Winfred C. Wang,Russell E. Ware,Scott T. Miller,Rathi V. Iyer,James F. Casella,Caterina P. Minniti,Sohail Rana,Courtney D. Thornburg,Zora R. Rogers,Ram Kalpatthi,Julio C. Barredo,R. Clark Brown,Sharada A. Sarnaik,Thomas H. Howard,Lynn W. Wynn,Abdullah Kutlar,F. Daniel Armstrong,Beatrice Files,Jonathan C. Goldsmith,Myron A. Waclawiw,Xiangke Huang,Bruce W. Thompson +21 more
TL;DR: Hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia, with some evidence for decreased acute chest syndrome, hospitalisation rates, and transfusion.
Journal ArticleDOI
Safety of Hydroxyurea in Children With Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial
Thomas R. Kinney,Ronald W. Helms,Erin E. O'Branski,Kwaku Ohene-Frempong,Winfred C. Wang,Charles Daeschner,Elliott Vichinsky,Rupa Redding-Lallinger,Beatrice E. Gee,Orah S. Platt,Russell E. Ware +10 more
TL;DR: This Phase I/II trial shows that HU therapy is safe for children with sickle cell anemia when treatment was directed by a pediatric hematologist and no life-threatening clinical adverse events occurred and no child experienced growth failure.
Journal ArticleDOI
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial.
Andrea Amalfitano,A.Resai Bengur,Richard P. Morse,Joseph M. Majure,Laura E. Case,Deborah L. Veerling,Joanne Mackey,Priya S. Kishnani,Wendy A. Smith,Alison McVie-Wylie,Jennifer A. Sullivan,George E. Hoganson,John Phillips,G. Bradley Schaefer,Joel Charrow,Russell E. Ware,Edward H. Bossen,Yuan-Tsong Chen +17 more
TL;DR: This phase I/II first study of recombinant human GAA derived from CHO cells showed that rhGAA is capable of improving cardiac and skeletal muscle functions in infantile GSD-II patients.
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.